Hayat Bähr-Mahmud - Concepedia

Author

Hayat Bähr-Mahmud

BioNTech (Germany)

Also Known As

Hayat Bähr-Mahmud

Publications

449

Citations

H-Index

Concepts

All Affiliations

BioNTech (Germany)Johannes Gutenberg University Mainz Georg Speyer Haus BioNTech (United States)University Medical Center of the Johannes Gutenberg University Mainz

About

Hayat Bähr-Mahmud is an author at BioNTech (Germany) specializing in immunotherapy, tumor biology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	363
2	Immunology	4	4	348
3	Cell Biology	2	2	60
4	Pathology	2	2	278
5	Biomolecular Engineering	1	1	15

Hayat Bähr-Mahmud

Publications

443

Citations

H-Index

Page 1

	Year	Citations
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies Christiane Stadler, Hayat Bähr-Mahmud, Leyla Çelik, Nature Medicine MedicineImmunologyPathologyAntibody EngineeringLarge Tumors	2017	266
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6 Christiane Stadler, Hayat Bähr-Mahmud, Laura M. Plum, OncoImmunology	2015	51
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6 Christiane Stadler, Ursula Ellinghaus, Leyla Fischer, Science Translational Medicine ImmunologyImmunoeditingImmunodominanceBiological TherapyImmunotherapeutics	2024	45
EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells Pranav Oberoi, Robert A. Jabulowsky, Hayat Bähr-Mahmud, PLoS ONE	2013	29
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane Stadler, OncoImmunology Tumor BiologyDrug TargetingOncologyMrna-encoded Anti-claudin 18.2Medicine	2023	25
Surface Charge-Modification Prevents Sequestration and Enhances Tumor-Cell Specificity of a Recombinant Granzyme B–TGFα Fusion Protein Robert A. Jabulowsky, Pranav Oberoi, Hayat Bähr-Mahmud, Bioconjugate Chemistry ImmunotherapeuticsCancer BiologyTumor BiologyTumor ImmunityCancer Cell Biology	2012	15
A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors. Kyriakos P. Papadopoulos, Mustapha Tehfé, Albiruni Ryan Abdul Razak, Journal of Clinical Oncology ImmunologyPathologyBiological TherapyPreliminary EfficacyImmunotherapy	2023	12

Page 1